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Summary
Gankyrin is an ankyrin repeat oncoprotein commonly overexpressed in hepatocellular carcinomas. Gankyrin interacts with
the S6 proteasomal ATPase and accelerates the degradation of the tumor suppressor Rb. We show here that gankyrin
has an antiapoptotic activity in cells exposed to DNA damaging agents. Downregulation of gankyrin induces apoptosis in
cells with wild-type p53. In vitro and in vivo experiments revealed that gankyrin binds to Mdm2, facilitating p53-Mdm2
binding, and increases ubiquitylation and degradation of p53. Gankyrin also enhances Mdm2 autoubiquitylation in the
absence of p53. Downregulation of gankyrin reduced amounts of Mdm2 and p53 associated with the 26S proteasome.
Thus, gankyrin is a cofactor that increases the activities of Mdm2 on p53 and probably targets polyubiquitylated p53 into
the 26S proteasome.S I G N I F I C A N C E
Gankyrin is overexpressed in most hepatocellular carcinomas. We show here that gankyrin is an antiapoptotic oncoprotein and
increases the degradation of p53 as well as Rb. Gankyrin binds to Mdm2, an E3 ubiquitin ligase for p53, and potentiates the ubiqui-
tylating activity. Gankyrin inhibits major tumor suppressors, and the attenuation of gankyrin expression induces apoptosis in tumor
cells. Therefore, gankyrin could be a good target for developing therapeutic and preventive strategies against human hepatocel-
luar carcinomas.Introduction
The ability of p53 to exert antiproliferative effects, including cell
cycle arrest and apoptosis, is strongly associated with its tu-
mor suppressor function (Hanahan and Weinberg, 2001; Vo-
gelstein et al., 2000). The ability of p53 to bind DNA and acti-
vate transcription is required for p53-dependent growth arrest.
p53 can mediate apoptosis by activating transcription of pro-
apoptotic genes and repressing transcription of antiapoptotic
genes (Johnstone et al., 2002; Vousden and Lu, 2002; Villunger
et al., 2003). p53 also controls apoptosis through transcription-
independent mechanisms (Mihara et al., 2003). Tight regulation
of p53 activity is imperative for maintaining normal cell growth
and preventing tumorigenesis, with too much or too little p53
contributing to diseases.
The degradation of p53 is regulated by the ubiquitin-protea-
some system (Brooks and Gu, 2003; Yang et al., 2004). In this
pathway, the first step in ubiquitin conjugation involves the
ATP-dependent activation of ubiquitin by a ubiquitin-activating
enzyme (E1) (Ciechanover et al., 2000; Pickart, 2001). The acti-
vated ubiquitin is then transferred from the E1 to a ubiquitin-CANCER CELL : JULY 2005 · VOL. 8 · COPYRIGHT © 2005 ELSEVIER INC.conjugating enzyme (E2). A ubiquitin-protein ligase (E3) then
facilitates transfer of ubiquitin from an E2 to the substrate.
Polyubiquitylated substrates are the preferred substrates of the
26S proteasome, whereas proteins modified by single or only
a few ubiquitin molecules appear to be long-lived in vivo or
are subject to alternative degradation pathways (Pickart, 2001).
Efficient polyubiquitylation has been suggested to require an
additional conjugating factor, named E4 (Koegl et al., 1999).
At least 5%–10% of all human tumors possess inappropriate
overexpression of Mdm2 (also called HDM2 in humans), and in
many of them, the p53 gene remains in its wild-type configura-
tion (Michael and Oren, 2003). Binding of Mdm2 to p53 re-
duces the transcriptional activity of p53. Mdm2 is an E3 for
p53 and enhances its degradation (Yang et al., 2004). Mdm2
also promotes conjugation of NEDD8 to p53 and represses its
transactivating activity (Xirodimas et al., 2004). Mdm2 itself is
the product of a p53-inducible gene, and this dependency cre-
ates an autoregulatory feedback loop in which both the activity
of p53 and the expression of Mdm2 are regulated (Chene,
2003). In vitro, Mdm2 catalyzes the addition of single ubiquitin
moieties to a cluster of six C-terminal lysines in p53 (Lai etDOI 10.1016/j.ccr.2005.06.006 75
A R T I C L EFigure 1. Antiapoptotic acitivity of gankyrin
A: Increased survival after exposure to etoposide (left) or adriamycin (middle), but not to TNF-α with cycloheximide (right). Three clones each of U-2 OS
cells stably expressing HA-gankyrin (B), HA-gankyrin isoform 2 (6), or HA alone (,) were counted at the indicated times after treatment. Data represent
mean ± SD of triplicates.
B: Decreased activation of caspase 8 and caspase 9. Caspase activities were determined in U-2 OS cells expressing HA-gankyrin or HA alone 4 hr after
treatment with etoposide as indicated. Data represent mean ± SD of triplicates.
C: Effects on survival of Huh-6 (left), PLC (middle), and HLE (right) HCC cells. Surviving cells expressing HA-gankyrin (striped bars), HA-gankyrin isoform 2
(white bars), or HA alone (black bars) were counted at the indicated times after etoposide treatment. Data represent mean ± SD of triplicates.
D: Effects on p53-induced apoptosis in H1299 cells that express gankyrin in the presence of doxycycline (Tet). After transfection with p53 expression
plasmids, cells were cultured in the presence (B) or absence (,) of Tet, and the survival (left) and caspase 9 activity (right) were assayed. Data represent
mean ± SD of triplicates.al., 2001; Rodriguez et al., 2000). Mdm2 does not efficiently
polyubiquitylate p53 under usual in vitro conditions, and the
E4 activity of p300 is required in addition to Mdm2 for p53
polyubiquitylation (Grossman et al., 2003). The activity of Mdm2
toward p53 is regulated by several mechanisms (Michael and
Oren, 2003). For example, phosphorylation of p53 reduces the
avidity of p53 for Mdm2 and thereby inhibits subsequent ubiq-
uitylation and degradation. Alternatively, covalent modification
of Mdm2 reduces its ability to promote the ubiquitylation and
degradation of p53 (Maya et al., 2001). The tumor suppressor
ARF binds to and functionally inactivates Mdm2 (Michael and
Oren, 2003).
Gankyrin (also known as PSMD10, p28, and Nas6p) is an
oncoprotein overexpressed in most hepatocellular carcinomas
(HCCs), and consists of seven ankyrin repeats (Higashitsuji et
al., 2000; Krzywda et al., 2004). Gankyrin binds to the retino-
blastoma gene product (Rb) and the S6 ATPase subunit of the
26S proteasome, and increases degradation of Rb in vitro and
in vivo (Higashitsuji et al., 2000; Dawson et al., 2002). Gankyrin
also binds to Cdk4 and counteracts the inhibitory function of
the tumor suppressors p16INK4A and p18INK4C (Dawson et al.,
2002; Li and Tsai, 2002). In a rodent model of hepatocarcino-
genesis, gankyrin is overexpressed from the earliest stage of
tumor development (Park et al., 2001). These findings suggest
that gankyrin is a major player in cell cycle control and tumori-
genesis in HCCs. Here, we have found that gankyrin, an in-
teractor with a protesomal ATPase, can also control the ubiq-
uitin ligase activity of Mdm2 on p53.76Results
Gankyrin increases resistance to apoptosis
induced by DNA damaging agents
Overexpression of gankyrin increases the tumorigenic potential
of immortalized NIH/3T3 cells (Higashitsuji et al., 2000). To con-
firm the transforming activity of gankyrin, we transfected pri-
mary rat embryonic fibroblasts (REFs) with plasmids express-
ing gankyrin in conjunction with activated Ras (Finlay, 1993).
10 to 14 days after transfection, multiple dense transformed
foci appeared in the dishes that received Ras and gankyrin,
whereas Ras or gankyrin alone did not induce a significant
number of foci (Supplemental Figure S1 and Supplemental Ta-
ble S1). Although the number and size of foci were smaller
compared with those induced by Ras and adenovirus E1A,
gankyrin cooperates with ras and transforms normal diploid fi-
broblasts.
One of the hallmarks of the cancer cell phenotype is evasion
of apoptosis (Hanahan and Weinberg, 2001). When gankyrin is
overexpressed in U-2 OS cells, the number of cells surviving
after exposure to etoposide or adriamycin was increased (Fig-
ure 1A). In contrast, no effect of gankyrin was observed in cells
treated with TNF-α and cycloheximide. DNA damage induces
p53-dependent apoptosis (Fridman and Lowe, 2003), whereas
TNF-α triggers apoptosis p53 independently (Varfolomeev and
Ashkenazi, 2004). In gankyrin-expressing U-2 OS cells, etopo-
side-induced cell surface expression of annexin V and activa-
tion of caspase 8 and caspase 9 were inhibited (Figure 1B and
data not shown), indicating that the increased survival was due
to the decreased apoptosis. We observed similar effects ofCANCER CELL : JULY 2005
A R T I C L Egankyrin in adriamycin-treated cells (data not shown). The anti-
apoptotic effect of gankyrin was observed in etoposide-treated
Huh-6 HCC cells expressing wild-type p53, but not in PLC and
HLE HCC cells expressing mutant p53 (Figure 1C). In p53 null
H1299 cells, introduction of p53 induced apoptosis and activa-
tion of caspase 9, which were inhibited by overexpression of
gankyrin (Figure 1D). These results suggest that gankyrin sup-
presses the proapoptotic signaling pathway mediated by p53.
Gankyrin suppresses transcriptional activity of p53
To probe the functional relationship between gankyrin and p53
in apoptosis, we first analyzed the effects of gankyrin on the
transcriptional activity of p53. We transfected normal diploid
WI-38 cells with a luciferase p53-cis reporter plasmid. Adria-Figure 2. Effects of gankyrin on activity and protein level of p53
A: Reduced transcriptional activity of p53. Left, WI-38 cells were cotransfected with a p53-responsive luciferase reporter, pRL-TK, and plasmids expressing
HA-gankyrin wild-type (wt), HA-gankyrin isoform 3, or HA vector. After exposure to adriamycin (ADR), luciferase activity was assayed. Middle, H1299 cells
were cotransfected and analyzed as above, except that plasmids expressing p53 were used instead of adriamycin. Right, WI-38 cells were cotransfected
and analyzed as above except that an AP-1-responsive luciferase reporter was used instead of a p53-responsive reporter. pFC-MEKK served as a positive
control. The results were normalized to Renilla luciferase activity, and represent the mean ± SD of triplicates.
B: Reduced induction of p53-inducible genes. U-2 OS cells were transfected with plasmids expressing HA-gankyrin or HA alone. After incubation with (+)
or without (−) ADR, gene expression was analyzed by Northern blotting using the indicated cDNA probes.
C: Effects on p53 levels. U-2 OS cells stably expressing HA-gankyrin (lane 2) or HA alone (lane 1), and U-2 OS cells (lanes 3 and 4) and Huh-7 cells (lanes 5
and 6) transiently transfected with plasmids expressing HA-gankyrin (lanes 4 and 6) or vector alone (lanes 3 and 5) were analyzed for p53 expression by
Western blotting (WB, upper) and Northern blotting (NB, lower) using indicated antibodies and cDNA probes.
D: Enhanced p53 degradation in vivo. 3 stable clones each of U-2 OS cells expressing HA-gankyrin (B) or HA alone (,) were treated with cycloheximide,
and harvested at the indicated time points. Lysates were analyzed by WB (upper panels). The intensity of the bands was quantified (bottom). Data
represent mean ± SD of triplicates.
E: Pulse chase experiment. H1299 cells cotransfected with plasmids expressing HA-gankyrin (B), HA-gankyrin isoform1 (6), or HA alone (,) and p53 were
pulse labeled with 35S-methionine. At indicated times, p53-immunoprecipitates were analyzed by SDS-PAGE and fluorography. The intensity of the bands
was quantified (bottom). As a loading control, 5% lysates were analyzed by Western blotting using anti-actin antibody. Data represent mean ± SD
of triplicates.CANCER CELL : JULY 2005mycin induced luciferase activity, which was suppressed dose
dependently by gankyrin (Figure 2A). In the p53 null H1299 and
Saos-2 cells that undergo apoptosis after introduction of p53
as well as adriamycin- or etoposide-treated U-2 OS cells, ex-
pression of gankyrin suppressed the reporter activity (Figure
2A and data not shown). The inhibition was specific to the p53
transactivation, since gankyrin did not affect a luciferase AP-
1-cis reporter activity. In U-2 OS cells exposed to adriamycin,
the mRNA levels of p53-inducible genes p21 and Mdm2, and
those involved in apoptosis, such as Noxa, PIG3, and Bax, but
not Perp, Killer, and Fas, were decreased by gankyrin (Figure
2B and data not shown).
The p53 protein level was decreased by gankyrin in U-2 OS
and Huh-7 cells expressing only wild-type and mutant p53, re-77
A R T I C L Espectively (Figure 2C). The level of p53 mRNA was not reduced
by gankyrin, suggesting that gankyrin affects the rate of syn-
thesis and/or the stability of p53 protein.
Gankyrin accelerates the Mdm2-dependent
degradation of p53
In U-2 OS cells stably overexpressing gankyrin, the stability
of endogenous p53 protein was decreased (Figure 2D). Pulse-
chase experiments confirmed that the half-life of ectopically
expressed p53 was shortened by gankyrin (Figure 2E). These
results demonstrate that gankyrin accelerates degradation of
p53 in vivo, and suggests that the decreased reporter activity
in the presence of gankyrin (Figure 2A) is due, at least partly,
to this effect.
The degradation of p53 is mainly mediated by Mdm2 (Yang
et al., 2004). In HeLa cells, however, p53 is predominantly de-
graded through the human papillomavirus (HPV)18 E6 pathway
(Hengstermann et al., 2001). Gankyrin did not decrease the p53
protein level in HeLa cells (Figure 3A). When p53-deficient
H1299 cells were transfected with plasmids that express
Mdm2-specific RNAi together with plasmids expressing p53
and gankyrin, the endogenous Mdm2 protein level was de-
creased and the suppressive effect of gankyrin on the p53 pro-
tein level was ameliorated (Figure 3B). These results suggest
that gankyrin promotes p53 degradation via Mdm2. To further
investigate this possibility, we utilized embryonic fibroblasts
from p53/mdm2 double-knockout mice (DKO-MEFs). As shown
in Figure 3C, the protein level of ectopically expressed p53 was
not affected by overexpression of gankyrin in the absence of
Mdm2. Mdm2 decreased the p53 level, which was further de-
creased by coexpression of gankyrin. The decrease in the p53Figure 3. Mdm2-dependent effects of gankyrin
on p53
A: Effects on p53 protein level in HeLa cells.
HeLa cells were transiently transfected with
plasmids expressing p53 and HA-gankyrin (lane
2) or vector alone (lane 1) as indicated. Cell ly-
sates were analyzed by Western blotting (WB).
B: Effects of decreased Mdm2. H1299 cells were
cotransfected with plasmids expressing RNAi
specific to wild-type (wt) or mutant (mut) Mdm2
mRNA (pSuper-Mdm2), p53, and FLAG-gankyrin
as indicated. Cell lysates were analyzed by WB.
C: Dependence on Mdm2. DKO-MEFs were
transfected with plasmids expressing human
p53, HA-Mdm2, and FLAG-gankyrin as indi-
cated. Levels of p53 were analyzed by WB.
p53:Mdm2 molar ratios were 4:1 in lanes 4 and
5, and 1:1 in lanes 6 and 7.
D: Effects on p53 stability. DKO-MEFs were trans-
fected with plasmids expressing human p53 and
Mdm2 (1:1 molar ratio) with (+,B) or without (−,
,) gankyrin, treated with cycloheximide, and
harvested at the indicated times. Lysates were
analyzed by WB using anti-p53 and anti-actin
antibodies (upper panels). The intensity of the
bands was quantified (bottom). Data represent
mean ± SD of triplicates.
E: Effects on p53 and AP-1 transcriptional activi-
ties. DKO-MEFs were transfected with a p53-
(left) or AP-1- (right) responsive luciferase repor-
ter, pRL-TK, and plasmids expressing human p53
and Mdm2 (p53:Mdm2, 1:1 molar ratio) and HA-gankyrin (+ and ++, a low and high dose, respectively) as indicated, and luciferase activity was assayed.
pFC-MEKK served as a positive control. The results were normalized to Renilla luciferase activity, and represent the mean ± SD of triplicates.78level was due to an increase in the degradation rate (Figure
3D). To analyze the effects on p53 transactivating activity, we
next transfected DKO-MEFs with plasmids expressing p53-
luciferase reporter, p53, gankyrin, and Mdm2. Luciferase activ-
ity was decreased by gankyrin in the presence, but not in the
absence, of Mdm2 (Figure 3E). No effect of gankyrin was ob-
served on AP-1-luciferase reporter activity. These results de-
monstrate that gankyrin accelerates degradation of p53 and
reduces its transcriptional activity in an Mdm2-dependent
manner.
Specific interaction of gankyrin with Mdm2
When we transfected U-2 OS cells with plasmids that ex-
pressed HA-tagged Mdm2 and FLAG-tagged gankyrin, Mdm2
coimmunoprecipitated with gankyrin (Figure 4A). The interac-
tion of FLAG-gankyrin and HA-Mdm2 was also observed in
DKO-MEFs (Figure 4B), indicating that the binding was not me-
diated by p53. Gankyrin was unable to coimmunoprecipitate
with MdmX, E6-AP, COP1, or Pirh2 (data not shown). Endoge-
nous gankyrin was also coimmunoprecipitated with Mdm2
from WI-38 cell lysates (Figure 4C). Notably, gankyrin was im-
munoprecipitated with anti-p53 antibody. GST pulldown assay
demonstrated a physical interaction of gankyrin with Mdm2,
but not p53, in vitro (Figure 4D).
By using a series of gankyrin deletion mutants and isoforms
lacking one or more ankyrin repeats (Hiroaki Higashitsuji and
Jun Fujita, unpublished data) in coimmunoprecipitation and
Western blot analysis, full-length gankyrin was found to be
necessary for binding to Mdm2 (Figure 4E). Similarly, the region
of Mdm2 necessary for binding to gankyrin was determined to
be the amino acid residues 412 to 437, which is adjacent toCANCER CELL : JULY 2005
A R T I C L EFigure 4. Interaction of gankyrin with Mdm2
A: Coimmunoprecipitation (IP) of exogenous proteins. U-2 OS cells were cotransfected with plasmids expressing FLAG-gankyrin and HA-Mdm2 as indicated.
Cell lysates (10% input) and immunoprecipitates prepared by IP with indicated antibodies were analyzed by Western blotting (WB). Arrows indicate
mobilities of HA-Mdm2 (upper) and FLAG-gankyrin (lower).
B: Co-IP in the absence of p53. DKO-MEFs were cotransfected with plasmids expressing FLAG-gankyrin and HA-Mdm2 as indicated. Lysates (10% input)
and immunoprecipitates prepared by IP with anti-HA or agarose-immobilized anti-FLAG antibody were analyzed by WB using the indicated antibodies.
C: Co-IP of endogenous proteins. Lysates from WI-38 cells (10% input) and immunoprecipitates prepared by IP with agarose-immobilized anti-Mdm2 (left)
or anti-p53 (right) antibody or normal mouse IgG were analyzed by WB using the indicated antibodies.
D: GST pulldown assays. GST-gankyrin fusion protein or GST was incubated with in vitro translated 35S-labeled Mdm2 (upper). GST-p53, GST-S6 (positive
control), or GST (negative control) was incubated with in vitro translated 35S-labeled gankyrin (lower). Bound proteins and 25% input were analyzed by
SDS-PAGE and fluorography.
E: Region of gankyrin necessary for binding to Mdm2. Gankyrin mutants and isoforms as indicated were expressed in U-2 OS cells, and assayed for co-IP
with HA-tagged full-length Mdm2. (+) and (−) indicate presence and absence, respectively, of binding. Top row, schematic structure of wild-type gankyrin.
N and C, the first and last ankyrin repeats, respectively. ANK1 to ANK5, the second to sixth ankyrin repeats.
F: Region of Mdm2 necessary for binding to gankyrin. Various Mdm2 mutants were expressed in U-2 OS cells, and assayed for co-IP with HA-tagged full-
length gankyrin. (+) and (−) indicate presence and absence, respectively, of binding. Top row, schematic structure of wild-type Mdm2 (modified from
Michael and Oren, 2003).
G: Cosedimentation of gankyrin, Mdm2, p53, and the 26S proteasome. The fractions generated by 10%–40% glycerol gradient centrifugation of lysates
from U-2 OS cells transfected with gankyrin RNAi (right) or control RNAi (left) were analyzed by WB using the indicated antibodies. Positions of markers are
shown on the top.
H: Co-IP of the proteasome subunits with gankyrin, Mdm2, and p53. IP with agarose-immobilized monoclonal anti-proteasomal α2 subunit antibody of
proteins in gradient fractions 7–15 from U-2 OS cells transfected with indicated RNAi. Precipitated proteins, 5% input, and whole cell lysates were separated
by SDS-PAGE and analyzed by WB using the indicated antibodies.CANCER CELL : JULY 2005 79
A R T I C L EFigure 5. Effects of gankyrin on p53 and apoptosis
A: Effects on p53 ubiquitylation. U-2 OS transfectants stably expressing HA-gankyrin or HA-vector alone were treated with MG132 for 6 hr. Cell lysates (5%
input) and immunoprecipitates prepared by immunoprecipitation (IP) with anti-p53 antibody were analyzed by Western blotting (WB) using the indicated
antibodies. p53(Ub)n indicates the mobility of ubiquitylated p53.
B: Effects of decreased gankyrin expression. Left, U-2 OS cells were transfected with pSuper-gankyrin that produces RNAi exactly matching (-wt1 and
-wt2) or 3-base-mismatching (-mut) to the gankyrin mRNA nucleotide sequence. Right, U-2 OS cells were transfected with pSuper-gankyrin-wt1 together
with plasmids expressing normal gankyrin from wild-type cDNA (wt) or 3-base-mutated cDNA (mwt). Cells were cultured in the presence or absence of
MG-132 and analyzed as in A.
C: Mdm2-dependent effect of gankyrin. DKO-MEFs were cotransfected with plasmids expressing p53, Mdm2, FLAG-gankyrin, and His-ubiquitin and cultured
in the presence (+) or absence (−) of MG132 as indicated. Cell lysates and those affinity-purified using Ni-NTA-agarose beads were analyzed by WB using
the indicated antibodies. Asterisk indicates nonspecific bands.
D: Apoptosis induced by decreased gankyrin expression. Left, Huh-6 cells were transfected with RNAi specific to wild-type (wt1 and wt2) gankyrin, mutated
(mut) gankyrin, wild-type (wt) p53, or mutated (mut) p53 mRNA. Cell lysates were prepared 2 days after transfection, and analyzed by WB using indicated
antibodies. Middle, Huh-6 cells were transfected with pSuper-gankyrin-wt1 (black columns) or -mut as a control (white columns). The cell numbers were
analyzed and expressed as relative to the control. Right, Lysates from Huh-6 cells transfected with indicated RNAi were assayed for caspase 9 activity. The
activity was expressed as relative to that induced by etoposide alone. Data represent mean ± SD of triplicates.
E: p53 dependency of apoptosis. Huh-6 cells were transfected with gankyrin-wt1 RNAi (,), gankyrin-wt1 RNAi plus p53 RNAi (6), gankyrin-mut RNAi (B),
or indicated RNAi. Cell numbers were counted at indicated times (left). Caspase 9 activity was assayed as in D (right). Data represent mean ± SD
of triplicates.the RING finger domain and different from the region for p53
binding (Figure 4F).
In U-2 OS cells, cosedimentation of endogenous gankyrin
with p53, Mdm2, and the 26S proteasome was observed dur-
ing glycerol gradient centrifugation of cell lysates (Figure 4G).
Furthermore, Western blot analysis of proteins coimmunopreci-
pitated from the fractions 7–15 with agarose-immobilized
monoclonal anti-proteasomal α2 subunit antibody revealed the
presence of gankyrin, p53, and Mdm2 (Figure 4H). Interest-
ingly, when gankyrin was knocked down by RNAi, both Mdm2
and p53 moved to lighter fractions during centrifugation (Figure
4G), and much lower amounts of Mdm2 and p53 were coim-80munoprecipitated with the proteasome, although the total cel-
lular amounts of Mdm2 and p53 were increased (Figure 4H).
These results indicate a direct interaction of gankyrin with
Mdm2 and suggest a gankyrin-Mdm2-mediated interaction of
p53 with the 26S proteasome.
Gankyrin enhances the Mdm2-dependent
ubiquitylation of p53
Because p53 is degraded through the ubiquitin-proteasome
pathway, we assessed the effect of gankyrin on ubiquitylation
of p53 in U-2 OS cells treated with a proteasome inhibitor. In
Western blot analysis of p53, a ladder of slowly migrating ubiq-CANCER CELL : JULY 2005
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A: Effects on mono- and polyubiquitylating activities of Mdm2. In vitro ubiquitylation assay was performed using gankyrin (low or high dose), p53, GST-
Mdm2, E1, E2, and His-ubiquitin as indicated. The products were analyzed by Western blotting (WB) using antibodies against p53. Short and long exposures
are shown. Arrow indicates the mobility of p53.
B: Effects of gankyrin isoform1 defective in binding to Mdm2. In vitro ubiquitylation assay was performed as in A and the products were analyzed by WB.
C: Effects of gankyrin in the presence of mutant Mdm2. In vitro ubiquitylation assay was performed as in A using GST-Mdm2 mutants instead of GST-Mdm2
wild-type (wt) in the presence (+) or absence (−) of GST-gankyrin or GST-p300N as indicated. The products were analyzed by WB using anti-p53 antibody.
Mdm2412–437 and Mdm2218–245 lack gankyrin binding activity and p300 binding activity, respectively.
D: Effects on p53 at high Mdm2:p53 ratio. In vitro ubiquitylation assay and WB were performed as in A using the Mdm2:p53 ratio of 4:1 instead of 1:1. The
reaction products were also immunoprecipitated (IP) with anti-p53 antibody or affinity-purified with Ni-NTA-agarose beads and analyzed by WB as indi-
cated. Asterisks indicate nonspecific bands.
E: Effects on p53-monoubiquitylating activity of Mdm2. Using methylated ubiquitin (Met), K48R, or UbK0 (right) instead of ubiquitin, in vitro ubiquitylation
assay was performed as in A. The products were analyzed by WB using anti-p53 and anti-ubiquitin antibodies as indicated.
F: Effects on autoubiquitylating activity of Mdm2. In vitro ubiquitylation assay was performed using gankyrin, GST-Mdm2, E1, E2, and His-ubiquitin in the
presence or absence of p53 as indicated. The products were affinity-purified with Ni-NTA-agarose beads or IP with anti-Mdm2 antibody, and analyzed by
WB using anti-Mdm2 antibody or polyubiquitin-specific anti-ubiquitin antibody, respectively.uitylated forms was more prominent in anti-p53 immunopreci-
pitates from gankyrin-expressing cells than those from control
cells, although the levels of endogenous p53 were comparable
(Figure 5A). Similar results were obtained when WI-38 cells
were cotransfected to express FLAG-gankyrin and His-ubiq-
uitin (Supplemental Figure S2). We next ablated endogenous
gankyrin expression and assessed its effects on p53 ubiqui-
tylation. When gankyrin-specific RNAi was expressed in U-2
OS cells, the levels of endogenous gankyrin and ubiquitylatedCANCER CELL : JULY 2005p53 were decreased, whereas those of p53, Mdm2, and p21
were increased (Figure 5B). Essentially similar results were ob-
tained in WI-38, A549, A2780, and 293 cells, and the level of
ubiquitylated p53 was decreased in both the cytoplasm and
nucleus in U-2 OS cells treated with gankyrin-specific RNAi
(data not shown). Gankyrin expressed from mutated mRNA
such that the gankyrin-specific RNAi cannot knockdown its ex-
pression abrogated the effect of RNAi on p53 ubiquitylation
(Figure 5B, right), suggesting that the effect on p53 is not due81
A R T I C L EFigure 7. In vivo effects of gankyrin on p53-ubiq-
uitylating and binding activities of Mdm2
A: Effects on mono- and polyubiquitylation of
p53. DKO-MEFs were cotransfected with plas-
mids expressing proteins as indicated and cul-
tured in the presence (+) or absence (−) of
MG132. Cell lysates (10% input) and those affin-
ity-purified using Ni-NTA-agarose beads were
analyzed by Western blotting (WB) using the in-
dicated antibodies. Asterisk indicates nonspe-
cific bands.
B: Effects of mutation in Mdm2. DKO-MEFs were
cotransfected with plasmids expressing indi-
cated proteins and analyzed as in A. HA-Mdm2
C464A has no E3 activity. Asterisk indicates non-
specific bands.
C: Effects on the level of Mdm2. DKO-MEFs were
cotransfected with plasmids expressing indi-
cated proteins and analyzed as in A.
D: Effects on the amount of p53 bound to
Mdm2. DKO-MEFs were cotransfected with plas-
mids expressing p53, HA-Mdm2, and FLAG-
gankyrin as indicated. Cells were cultured in the
presence or absence of MG132. Cell lysates
were prepared and immunoprecipitated with
anti-p53 or anti-HA antibody. Immunoprecipi-
tates and cell lysates (10% input) were analyzed
by WB.
E: GST pulldown assay. GST-Mdm2 was incu-
bated with p53 in the presence of increasing
amounts of gankyrin as indicated. Proteins
bound to glutathione-Sepharose as well as 10%
of recombinant proteins incubated with GST-
Mdm2 (10% input) were analyzed by WB.to the off-target effects of RNAi. The observed effects of gank-
yrin were dependent on Mdm2, since ubiquitylation of exoge-
nous p53 was increased by gankyrin only in the presence of
Mdm2 in DKO-MEFs (Figure 5C).
Gankyrin is commonly overexpressed in HCCs (Higashitsuji
et al., 2000). Therefore, we examined the effects of gankyrin
RNAi in HCC cell lines Huh-6 and Huh-7, expressing wild-type
and mutant p53, respectively. In Huh-6 cells, gankyrin RNAi
decreased the gankyrin expression, increased the p53 protein
level, and induced apoptosis with activation of caspase 9 (Fig-
ure 5D). This proapoptotic activity was abrogated by concomi-
tant suppression of p53 expression (Figure 5E), indicating its82dependence on p53. No proapoptotic effect was observed in
Huh-7 cells (data not shown). Gankyrin RNAi induced apopto-
sis in U-2 OS cells and A549 cells with wild-type p53, but not
in p53 null H1299 cells or HeLa cells (data not shown). These
results suggest that overexpression of gankyrin in tumor cells
decreases the p53 protein level by enhancing its ubiquitylation
and degradation by Mdm2, resulting in inhibition of p53-
dependent apoptosis.
Gankyrin enhances the E3 activity of Mdm2
We next investigated whether gankyrin has intrinsic E3 ubiq-
uitin ligase activity by an in vitro ubiquitylation assay. WhenCANCER CELL : JULY 2005
A R T I C L EFigure 8. Effects of gankyrin on posttranslational
modifications and subcellular localization of p53
A: Effects on DNA damage-induced phosphory-
lation of p53. U-2 OS cells stably overexpressing
HA-gankyrin or HA alone (mock) were treated
with adriamycin, and cell lysates were analyzed
by Western blotting (WB) using antibodies as in-
dicated.
B: Suppression of p300-induced acetylation of
p53. REFs were cotransfected with plasmids ex-
pressing human p53, HA-p300, and FLAG-gank-
yrin, cultured, and treated with trichostatin A
(TSA) (+) or vehicle alone (−) in the presence of
MG132. Cell lysates were immunoprecipitated
with agarose-immobilized antibody specific to
human p53 and analyzed by WB.
C: Effects on localization of p53. Left, DKO-MEFs
were transfected with plasmids expressing
EGFP-p53, HA-Mdm2 (low and high doses), and
FLAG-gankyrin in the presence (+) or absence
(−) of MG132 as indicated. Localization of EGFP-
p53 fluorescence was determined in 300 cells
for each culture. Ordinate shows the percen-
tage of cells with localization of EGFP-p53
mainly in the nucleus (white columns) or cyto-
plasm (black columns). nd, no EGFP-p53 de-
tected. Data represent mean ± SD of triplicates.
Right, photographs of representative cells trans-
fected with EGFP-p53 alone (nuclear localiza-
tion, top), in combination with low-dose Mdm2
(cytoplasmic, middle) or low-dose Mdm2 plus
gankyrin (nd, bottom) observed under confo-
cal microscope.affinity-purified GST-gankyrin was incubated in ubiquitin reac-
tion buffer that contained recombinant E1, E2 (UbcH5a or
UbcH5b), and ubiquitin, no autoubiquitylation of gankyrin was
observed (data not shown). When we incubated gankyrin with
p53 in ubiquitin reaction buffer, no detectable change in p53
migration was observed (Figure 6A). However, gankyrin dose
dependently increased the formation of mono- and polyubiqui-
tylated p53 in the presence of Mdm2. Gankyrin isoform 1 lack-
ing Mdm2 binding activity showed no effect on ubiquitylation
of p53 (Figure 6B). Ubiquitylation of p53 induced by mutant
Mdm2 lacking its gankyrin binding region (Mdm2412–437)
was increased in the presence of p300, but not gankyrin (Fig-
ure 6C). These results indicate that gankyrin has no intrinsic E4
activity and that binding to Mdm2 is necessary for gankyrin to
increase ubiquitylation of p53. Since mutant Mdm2, which was
unable to bind p300 but able to bind gankyrin (Mdm2218–
245), polyubiquitylated p53 in the presence of gankyrin (Figure
6C), the E4 activity of p300 was unlikely to be involved in the
observed effect of gankyrin. These in vitro assays were per-
formed using the Mdm2:p53 molar ratio of 1:1 (low Mdm2).
At 4:1 molar ratio (high Mdm2), polyubiquitylation of p53 was
observed in the absence of gankyrin, and it was further in-
creased by gankyrin (Figure 6D).
When methylated ubiquitin was used instead of ubiquitin in
an in vitro ubiquitylation assay, the ladder of monoubiquitylated
p53 species was increased in the presence of gankyrin (FigureCANCER CELL : JULY 20056E). Similar results were obtained using ubiquitin-K48R or
UbK0 in which all seven lysine residues were replaced by argi-
nine. These results demonstrate that gankyrin enhances mono-
and polyubiquitylating activities of Mdm2 toward p53. Interest-
ingly, gankyrin increased autoubiquitylating activity of Mdm2 in
the absence, but not in the presence, of p53 (Figure 6F).
Essentially similar findings were made in DKO-MEFs. When
Mdm2 plasmids were transfected at a low dose, gankyrin
caused an increase in polyubiquitylation of p53 dose depen-
dently (Figure 7A). When Mdm2 plasmids were transfected at
a high dose, mono- and polyubiquitylation of p53 were ob-
served, which were further increased by gankyrin (Figure 7B).
Gankyrin enhanced the p53-ubiquitylating activity of Mdm2218–
245, but not Mdm2412–437 lacking the ability to bind gankyrin.
Although the acidic domain of Mdm2 has been shown to be
critical in the ubiquitylation of p53 (Meulmeester et al., 2003;
Kawai et al., 2003), gankyrin increased the level of ubiqui-
tylated p53 induced by Mdm2218–321.
In DKO-MEFs, the exogenous Mdm2 level was not affected
by gankyrin in the presence of p53 (Figure 7C). In the absence
of p53, however, ubiquitylation of Mdm2 was increased and
the Mdm2 protein level was decreased.
When gankyrin was overexpressed in DKO-MEFs, the p53
level decreased, but significantly more Mdm2 was coimmuno-
precipitated with p53 compared with those not transfected
with gankyrin-expressing plasmids (Figure 7D). When the deg-83
A R T I C L Eradation of p53 was inhibited by proteasome inhibitors, more
Mdm2 and p53 were coimmunoprecipitated in cells expressing
gankyrin. In vitro GST pulldown assay definitely demonstrated
that gankyrin facilitates binding of Mdm2 to p53 (Figure 7E).
Effects of gankyrin on posttranslational
modification of p53
The stability and activity of p53 are affected by posttransla-
tional modifications (Brooks and Gu, 2003). Phosphorylation of
multiple serine residues of p53 has been proposed to interfere
with the ability of Mdm2 to negatively regulate p53. Gankyrin
did not affect phosphorylation of these residues (Figure 8A).
Gankyrin did not affect phosphorylation of Mdm2 at Ser166
and Ser186 either (data not shown), although these modifica-
tions are known to affect the activity of Mdm2 (Michael and
Oren, 2003).
p53 is specifically acetylated at multiple lysine residues of
the C-terminal regulatory domain by p300/CBP, and the acety-
lation levels of p53 correlate well with its activation and stabili-
zation induced by stress (Brooks and Gu, 2003; Ito et al., 2002).
Mdm2 negatively regulates the p300-induced p53 acetylation
(Chene, 2003). Gankyrin also reduced the p300-dependent p53
acetylation in REFs (Figure 8B). The effect was reversed by a
pan-histone deacetylase inhibitor trichostatin A, suggesting
that active deacetylation is involved in the decrease in the level
of acetylated p53.
A number of studies have shown that nuclear export of p53
is specifically regulated by Mdm2 (Chene, 2003). As shown in
Figure 8C, ectopic expression of wild-type p53 fused to EGFP
yielded predominantly nuclear localization of p53 in DKO-
MEFs. Gankyrin alone had no effect on the localization. Con-
sistent with the report by Li et al. (2003), low Mdm2 increased
cytoplasmic localization of p53-EGFP, and at high Mdm2, no
EGFP signal was detected (Figure 8C). In the presence of
gankyrin, however, p53-EGFP was not detected even with low
Mdm2. Taken together, the present study has demonstrated
that gankyrin is an antiapoptotic oncoprotein that binds to and
enhances activities of Mdm2, resulting in suppression of p53.
Discussion
We have found that the oncoprotein gankyrin reduces the level
of the p53 protein by increasing its ubiquitylation and degrada-
tion. Several E3 ubiquitin ligases are known for p53, including
Mdm2, COP1, Pirh2, and p300 (Grossman et al., 2003; Leng
et al., 2003; Dornan et al., 2004). Experiments using Mdm2
null DKO-MEFs demonstrated that the effects of gankyrin are
Mdm2-dependent. Gankyrin directly binds to Mdm2, and en-
hances its ubiquitylating activity toward p53. The activities of
Mdm2 are regulated by several mechanisms positively or nega-
tively (Yang et al., 2004; Michael and Oren, 2003; Wu et al.,
2004). Mdm2-interacting proteins such as ARF, YY1, hHR23A,
MdmX, MTBP, and Cul4A can affect the Mdm2-mediated deg-
radation of p53 (Michael and Oren, 2003; Brignone et al., 2004;
Nag et al., 2004; Brady et al., 2005). Gankyrin did not affect
the phosphorylation, ubiquitylation, or protein level of Mdm2 in
the presence of p53. There is now evidence that trans- and
autoubiquitylating activity of Mdm2 can be differentially regu-
lated through its interaction with other proteins. The tumor sup-
pressor ARF binds to Mdm2 and preferentially inhibits its p53-
ubiquitylating activity (Xirodimas et al., 2001). Gankyrin may84increase Mdm2 function by displacing ARF. However, this is
unlikely, because gankyrin did not affect the binding of ARF to
Mdm2 (Hiroaki Higashitsuji and Jun Fujita, unpublished data)
and the ARF binding region of Mdm2 (Michael and Oren, 2003)
is different from that for gankyrin. Recently, YY1 has been sug-
gested as a cofactor for Mdm2, facilitating Mdm2-p53 interac-
tion, p53 polyubiquitylation, and degradation (Sui et al., 2004;
Gronroos et al., 2004). In contrast to gankyrin, YY1 directly
binds to p53 and ARF as well.
Mdm2 efficiently induces monoubiquitylation, but not poly-
ubiquitylation, of p53 in vitro (Lai et al., 2001). p300 binds to
Mdm2 and shows the E4 activity, promoting the polyubiquityla-
tion of p53 (Grossman et al., 2003). The E4 activity has been
suggested to represent a specialized type of E3 activity (Hata-
keyama et al., 2001), and p300 indeed has an autoubiquitylat-
ing E3 activity (Grossman et al., 2003). Gankyrin promoted
both mono- and polyubiquitylation of p53 by Mdm2 in a p300-
independent manner, but showed no E3 or E4 activity. Direct
interaction between gankyrin and Mdm2 was necessary to en-
hance p53 ubiquitylation, and gankyrin facilitated the binding
of Mdm2 to p53 in vivo and in vitro, suggesting that gankyrin
causes a conformational change(s) in bound Mdm2. Since
gankyrin also enhanced Mdm2 autoubiquitylation and degra-
dation in the absence of p53, gankyrin probably has some di-
rect effect on the E3 activity of Mdm2, the exact nature of
which remains to be resolved.
Gankyrin also seems to exert a postubiquitylation effect on
p53. Previously, evidence has been presented for the binding
to the 26S proteasome of ubiquitin ligases and proteins with
ubiquitin-like domains, which may in turn bind to ubiquitylated
proteins (Brignone et al., 2004; Hartmann-Petersen et al.,
2003). Forming a complex with the 26S proteasome, endoge-
nous gankyrin cosedimented with p53 and Mdm2 during glyc-
erol centrifugation of U-2 OS cell lysates (Figure 4G). Further-
more, downregulation of gankyrin resulted in dissociation of
most Mdm2 and p53 from the 26S proteasome (Figure 4H).
Although little of the cellular gankyrin was found in complex
with Mdm2, these results suggest that gankyrin assists in the
targeting of an E3 ubiquitin ligase (Mdm2) and its ubiquitylated
substrate (p53) directly to a proteasomal ATPase (S6), to en-
sure efficient unfolding of the protein target and degradation.
Recently, low Mdm2 has been shown to induce monoubiqui-
tylation and nuclear export of p53, whereas high Mdm2 pro-
motes p53’s polyubiquitylation and nuclear degradation (Li et
al., 2003). In DKO-MEFs, we found that in the presence of
gankyrin, low Mdm2 degrades p53 like high Mdm2 (Figure 8C).
Acetylation of the C-terminal lysine residues of p53 prevents
Mdm2-dependent ubiquitylation (Michael and Oren, 2003), and
Mdm2 reduces p300/CBP-mediated p53 acetylation, either by
directly interfering with activities of p300/CBP or through re-
cruitment of the histone deacetylase HDAC1 (Ito et al., 2002).
We found that active deacetylation is involved in the suppres-
sion of p300-induced acetylation of p53 by gankyrin (Figure
8B). However, whether it is also due to enhanced activity of
Mdm2 is presently unknown. Also unknown is a possible effect
of gankyrin on Rb-ubiquitylating activity of Mdm2 (Uchida et
al., 2005).
Viral oncoproteins such as HPV E7 and adenovirus E1A
block the function of Rb, which results in the production of the
ARF, leading to stabilization of p53 (Vousden and Lu, 2002;
Michael and Oren, 2003). The viruses counteract these cellularCANCER CELL : JULY 2005
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such as HPV E6 and adenovirus E1B, leading finally to tumor
formation (Yang et al., 2004). Gankyrin binds to and inhibits
Rb (Higashitsuji et al., 2000). Gankyrin also inhibited p53 and
functioned as a transforming gene. Furthermore, reducing
gankyrin expression induced apoptosis in HCC cells with wild-
type p53. p53 mutation is not frequent in HCCs, especially in
low-grade or low-stage HCCs, compared with other types of
tumors (Konishi et al., 1993). Considering its function and com-
mon overexpression in HCCs, gankyrin must play important
roles in hepatocarcinogenesis, and blocking gankyrin may
prove to be a valuable therapeutic and/or preventive strategy
against human HCCs.
Experimental procedures
Cell culture and apoptosis assays
Mouse NIH/3T3 cells, DKO-MEFs (kindly provided by D.P. Lane), REFs, hu-
man U-2 OS, Saos-2, HeLa, H1299, A549, A2780, T24, adenovirus-trans-
formed human embryonic kidney 293 cells, WI-38 normal diploid embryonic
fibroblasts, and HCC cell lines (p53 status as reported by Jia et al., 1997),
Huh-6 (wild-type p53), Huh-7 (Y220C p53), PLC (R249S p53), and HLE
(V272M p53) were maintained in Dulbecco’s modified Eagle medium or
RPMI1640 medium supplemented with 10% fetal bovine serum at 37°C in
a humidified atmosphere of 5% CO2 in air. Induction and analysis of apo-
ptosis, including assays for caspase 8 and 9 activities, transfection, isola-
tion of stable clones, and immunofluorescence staining were performed as
described (Higashitsuji et al., 2000; Higashitsuji et al., 2002; Nagao et al.,
2003). For evaluation of p53 localization, 300 cells were scored for each
condition under a fluorescence microscope.
Reporter gene assay
Luciferase reporter plasmids containing p53- or AP-1 binding sites (p53-
Luc or pAP-1-Luc, respectively, Stratagene) and pRL-TK (Promega) were
cotransfected with increasing amounts of HA-gankyrin or its isoform cDNA
in expression vector pCMV4-3HA or vetor alone as described (Higashitsuji
et al., 2002). 24 hr later, cells were assayed for luciferase activity or treated
with etoposide or adriamycin and assayed 12 hr later. Luciferase activity
was measured by the Luciferase Assay System (Promega) according to the
manufacturer’s protocol. In some experiments, plasmids expressing p53
and/or Mdm2 were cotransfected as well. pFC-MEKK plasmid (Stratagene)
served as a positive control for the AP-1 reporter assay.
Analyses of gene expression and protein-protein interactions
RNA extraction, Northern blot analysis, immunoprecipitation, Western blot
analysis, and immunofluorescence staining of cells were performed as de-
scribed (Higashitsuji et al., 2002; Nagao et al., 2003). For immunoprecipita-
tion, anti-p53 antibody (DO-1 and FL-393, Santa Cruz), anti-HA antibody
(12CA5, Roche), anti-FLAG antibody (M2, Sigma), agarose-immobilized
monoclonal anti-proteasomal α2 subunit antibody (Affiniti Research Prod-
ucts), agarose-immobilized anti-p53 antibody (DO-1, Santa Cruz), agarose-
immobilized anti-FLAG antibody (M2, Sigma), and agarose-immobilized
anti-Mdm2 antibody (SMP14, Santa Cruz) were used. Western blot analysis
was performed using the antibody against p53 (DO-1, Santa Cruz; DO-7,
PharMingen), gankyrin (Santa Cruz), β1 and Rpt1/S7 (Affiniti Research Prod-
ucts), HA, FLAG, β-actin (C4, Chemicon), ubiquitin (FL-76, Santa Cruz),
Mdm2 (SMP14, Santa Cruz), acetylated lysine (Cell Signaling Technology),
and acetylated p53 (Lys 320, Lys 373/382) (Upstate). The anti-ubiquitin anti-
body FK2 (MBL, Nagoya, Japan) recognizes polyubiquitin, but not mono-
ubiquitin.
Glycerol gradient centrifugation of cell lysates was performed as de-
scribed (Dawson et al., 2002). For GST pulldown assays, full-length gank-
yrin cDNA and Mdm2 cDNA was cloned into the expression vector pGEX-
4T (Amersham Pharmacia) and expressed in E. coli. GST-gankyrin fusion
protein and GST were immobilized on glutathione-Sepharose and incu-
bated with in vitro translated 35S-labeled Mdm2 proteins at 4°C for 60 min.
Bound proteins were analyzed by SDS-PAGE and fluorography as de-
scribed (Higashitsuji et al., 2000). GST-Mdm2 was incubated with recombi-CANCER CELL : JULY 2005nant p53 and gankyrin at a molar ratio of 1:1:0, 1:1:0.5, 1:1:1, or 1:1:2. After
short incubation, proteins bound to glutathione-Sepharose were recovered
and directly analyzed by Western blotting.
To determine the regions of gankyrin necessary for binding to Mdm2,
plasmids expressing various deletion mutants tagged with FLAG were co-
transfected with plasmids expressing HA-tagged full-length Mdm2 onto
U-2 OS cells. Lysates were prepared from them, immunoprecipitated with
anti-HA antibody, and analyzed by Western blotting using anti-FLAG anti-
body. The regions of Mdm2 necessary for binding to gankyrin were deter-
mined similarly.
Analysis of p53 stability
For the in vivo p53 degradation assay, 80%–90% confluent cultures of U-2
OS cells stably expressing HA-gankyrin or HA alone (3 clones each) were
incubated with cycloheximide (100 g/ml). After 20, 40, and 80 min, the
cells were harvested and subjected to Western blot analysis using the anti-
p53 antibody. The intensity of the bands was quantified by densitometry.
To study the stability of exogenous p53 protein, DKO-MEFs were cotrans-
fected with plasmids expressing p53 and Mdm2 with or without gankyrin,
treated with cycloheximide, and analyzed as above.
For pulse chase analysis, H1299 cells were cotransfected with plasmids
expressing p53 with or without gankyrin-expressing plasmids. After 18 hr,
the transfected cells were metabolically labeled with 35S-methionine/cys-
teine for 30 min. Subsequently, cells were washed and chased in nonradio-
active medium for various periods of times. The cell lysates containing the
same amount of trichloroacetic acid-insoluble radioactivity were immuno-
precipitated with anti-p53 antibody (FL-393), and analyzed by SDS-PAGE
and fluorography.
In vitro and in vivo ubiquitylation assays
In vitro ubiquitylation assays were carried out in ubiquitin reaction buffer (50
mM Tris-HCl, 2 mM ATP, 5 mM MgCl2, 2 M DTT) with rabbit E1 (200 ng,
Boston Biochem), UbcH5a or UbcH5b (100–200 ng, Boston Biochem), and
His-tagged ubiquitin, methylated ubiquitin, ubiquitin-K48R, or ubiquitinK0
(10 g, Boston Biochem) in the presence or absence of ubiquitin aldehyde
(25 ng/ml, Affinity Research Products). The cDNAs for p53, gankyrin,
Mdm2, and their mutants were cloned into pGEX6P-1 (Amersham Phar-
macia Biotech) and expressed as GST-fusion proteins in Escherichia coli
strain BL21. Where indicated, the GST was cleaved using the PreScission
protease. The Mdm2:p53 molar ratio used was 1:1, 2:1, or 4:1. The reac-
tions were incubated at 30°C for 30–90 min. The reactions were stopped
with 2× SDS loading buffer and heated to 95°C for 5 min, and the proteins
were separated on a 5%–10% SDS-PAGE. In some experiments, the reac-
tion products were immunoprecipitated with anti-p53 antibody (FL393) or
affinity-purified with Ni-NTA-agarose beads (Xirodimas et al., 2001). Ubiqui-
tylated proteins were visualized by Western blot analysis. To assess the
effect of gankyrin or p300 on E3 activity of Mdm2, Mdm2 was incubated
with GST-gankyrin or GST-p300N proteins for 1 hr at 4°C prior to incubation
with the ubiquitin reaction buffer.
For in vivo ubiquitylation assay, H1299 cells or DKO-MEFs (in 60 mm
dish) were cotransfected with plasmids expressing p53 (1.0 g), FLAG-
gankyrin (0.5, 1.0, or 2.0 g), HA-Mdm2 or its mutant (0.5, 1.0, or 2.0 g),
and His-tagged ubiquitin in various combinations. Prior to collection after
48 hr, cells were treated with MG132 (25 M) for 6 hr. Then, cells were lysed
in modified RIPA buffer (10 mM Tris-HCl [pH 7.5], 5 mM EDTA, 150 mM
NaCl, 1% NP-40, 1% sodium deoxycholate, 0.025% SDS, and proteinase
inhibitors), and lysates were immunoprecipitated with anti-p53 antibody
(FL393) or affinity-purified with Ni-NTA-agarose beads (Xirodimas et al.,
2001) and analyzed by Western blotting.
In vivo acetylation assay
Cells were lysed in buffer (20 mM Tris-HCl [pH 7.6], 170 mM NaCl, 1 mM
EDTA, 0.5% NP-40, 1 M DTT) supplemented with 5 M trichostatin A and
proteinase inhibitors. To detect acetylated human p53, equal amounts of
cell lysates (250–500 g proteins) were incubated with 1 g of agarose-
immobilized antibody specific to human p53 (DO-1) for 4 hr at 4°C. Precipi-
tated proteins were analyzed by Western blotting.
Inhibition of endogenous gene expression by RNAi
For production of RNAi within the cells, we used the pSuper vector as de-
scribed (Higashitsuji et al., 2002). pSuper-gankyrin-wt1 and pSuper-gank-85
A R T I C L Eyrin-wt2 contained the 19 nucletides (nt) derived from the gankyrin cDNA
(nt number 456 to 474, and 205 to 223, respectively; GenBank accession
number D83197) as the target sequence. The control pSuper-gankyrin-mut
contained mutations at gankyrin cDNA nt numbers 461 (C to T), 462 (A to
T), and 468 (A to T). Double-stranded RNAs corresponding to those ex-
pressed by pSuper-gankyrin-mut, pSuper-gankyrin-wt1, and pSuper-gank-
yrin-wt2 (gankyrin-mut RNAi, gankyrin-wt1 RNAi, and gankyrin-wt2 RNAi,
respectively) were synthesized and transfected using the SiPORT Amine
Transfection Agent (Ambion). Double-stranded RNA containing scrambled
19 nt was used as a control. To avoid inhibition by pSuper-gankyrin-wt1 but
express normal gankyrin protein, 3 point mutations were introduced into nt
numbers 471, 473, and 474 of gankyrin cDNA and cloned into expression
vector. pSuper-Mdm2-wt and pSuper-p53 contained the 19 nt derived from
the Mdm2 cDNA (nt numbers 402 to 420, GenBank accession number
Z12020) and the p53 cDNA (nt numbers 989 to 1007, GenBank accession
number K03199), respectively, as the target sequence. The control pSuper-
p53-mut contained mutations at p53 cDNA nt numbers 993 (C to T), 994
(C to T), and 1001 (A to T). Double-stranded RNAs p53 RNAi and p53 mut
RNAi corresponding to those expressed by pSuper-p53 and pSuper-p53-
mut, respectively, were also synthesized and used. The control pSuper-
Mdm2-mut contained mutations at Mdm2 cDNA nt numbers 404 (G to A)
and 413 (T to G). Transfections of pSuper plasmids were performed using
Fugene6 Reagent (Roche).
Supplemental data
Supplemental data for this article can be found at http://www.cancercell.
org/cgi/content/full/8/1/75/DC1/.
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